Hepatitis C virus recurrence after liver transplantation in Hungary. Trends over the past 10 years;Hepatitis C-vírus-fertozés kiújulása májátültetés után. Mi változott az elmúlt 10 évben?

Orvosi Hetilap

Volumn 154, Issue 27, 2013, Pages 1058-1066

  Gelley, Fanni ^a   Gámán, György ^a   Gerlei, Zsuzsanna ^a   Zádori, Gergely ^a   Görög, Dénes ^a   Kóbori, László ^a   Fehérvári, Imre ^a   Schuller, János ^c   Szonyi, László ^b   Nagy, Péter ^b   Doros, Attila ^a   Fazakas, János ^a   Lengyel, Gabriella ^b   Schaff, Zsuzsa ^b   Kiss, András ^b   Sárváry, Eniko ^a   Nemes, Balázs ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c Patológiai És Kísérleti Rá kkutató Intézet Budapest ^*  (Hungary)

Author keywords

Antivir lis kezel s; Antiviral treatment; Hepatitis C virus; Hepatitis C v rus; Liver transplantation; M j t ltet s; Recurrence; Rekurrencia

Indexed keywords

ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DONOR; GRAFT RECIPIENT; GRAFT SURVIVAL; HEPATITIS C; HEPATITIS C VIRUS; HISTOLOGY; HUMAN; HUNGARY; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; POSTOPERATIVE COMPLICATION; RECURRENCE FREE SURVIVAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; DIABETES MELLITUS; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEPACIVIRUS; HEPATITIS C; HUMANS; HUNGARY; INCIDENCE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84880380177     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2013.29647     Document Type: Article

References (36)

1. Gane, E. J.: The natural history of recurrent hepatitis C and what influences this. Liver Transpl., 2008, 14 (Suppl. 2), S36-S44.
2. Nemes, B., Srvry, E., Kbori, L., et al.: The demographic, perioperative and mortality characteristics of the Hungarian Liver Transplant Program. [A hazai mjtltetsi program demogrfiai, perioperat-v s mortalitsi adatai.] Orv. Hetil., 2005, 146, 1423-1432. [Hungarian]
3. Germani, G., Tsochatzis, E., Papastergiou, V., et al.: HCV in liver transplantation. Semin. Immunopathol., 2013, 35, 101-110.
4. Yilmaz, N., Schiffman, M. L., Stravitz, R. T., et al.: A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl., 2007, 13, 975-983.
5. Burra, P.: Hepatitis C. Semin. Liver Dis., 2009, 29, 53-65.
6. Bizollon, T., Pradat, P., Mabrut, J. Y., et al.: Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C.. Am. J. Transplant., 2005, 5, 1909-1913.
7. Berenguer, M.: Systematic rewiev of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J. Hepatol., 2008, 49, 274-287.
8. Nemes, B., Srvry, E., Kbori, L., et al.: Serum hepatitis C virus-ribonucleotide acid monitoring after liver transplantation. The Hungarian experience. Dig. Liver Dis., 2005, 37, 68-69.
9. Nemes, B., Srvry, E., Gerlei, Zs., et al.: The recurrence of hepatitis C virus after liver transplantation. [Hepatitis C v-rus kijulsa mjtltets utn.] Orv. Hetil., 2007, 148, 1971-1979. [Hungarian]
10. Nemes, B., Gelley, F., Zdori, G., et al.: The role of marginal donors in liver transplantation. The Hungarian experience. [A marginlis donorok szerepe mjtranszplantcinl - hazai gyakorlat.] Orv. Hetil., 2009, 150, 2228-2236. [Hungarian]
11. Recommendation for the diagnosis and antiviral treatment of hepatitic C virus infection. [Ajnls a C-v-rus hepatitis diagnosztikjra s v-rusellenes kezelsre.] Gasztroenterolgiai Szakmai Kollgium, 2012. http://mob.gyemszi.hu/ detailsperm.jsp?PERMID=103822
12. Nemes, B., Gelley, F., Zdori, G., et al.: Outcome of liver transplantation based on donor graft quality and recipient status. Transplant. Proc., 2010, 42, 2327-2330.
13. Berenguer, M., Lpez-Labrador, F. X., Wright, T. L.: Hepatitis C and liver transplantation. J. Hepatol., 2001, 35, 666-678.
14. Pelletier, S. J., Iezzoni, J. C., Crabtree, T. D., et al.: Prediction of liver allograft fibrosis after transplantation for hepatitis C virus: persistent elevation of serum transaminase levels versus necroinflammatory activity. Liver Transpl., 2000, 6, 44-53.
15. Firpi, R. J., Abdelmalek, M. F., Soldevila-Pico, C., et al.: One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl., 2004, 10, 1240-1247.
16. Saraf, N., Fiel, M. I., Deboccardo, G., et al.: Rapidly progressive recurrent hepatitis C virus infection starting 9 days after liver transplantation. Liver Transpl., 2007, 13, 913-917.
17. Nemes, B.: Some factors, with an impact on the outcome of the Hungarian Liver Transplantation Program, with special consideration of the hepatitis C virus. [A magyar mjtltetsi program eredmnyeit befolysol tnyezk, klns tekintettel a hepatitis C v-rusra.] Magy. Seb., 2008, 61, 42-47. [Hungarian]
18. Forman, L. M., Lewis, J. D., Berlin, J. A., et al.: The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology, 2002, 122, 889-896.
19. Thuluvath, P., Krok, K., Segev, D., et al.: Trends in post-liver transplant survival in patients with hepatitis C between 1991 and 2001 in the United States. Liver Transpl., 2007, 13, 719-724.
20. Mutimer, D. J., Gunson, B., Chen, J., et al.: Impact of donor age and year of transplantation on graft and patient survival following liver transplantation for hepatitis C virus. Transplantation, 2006, 81, 7-14.
21. Neff, G. W., OBrien, C. B., Nery, J., et al.: Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infection. Liver Transpl., 2004, 10, 1497-1503.
22. Watt, K. D., Lyden, E. R., McCashland, T. M., et al.: Poor survival after liver retransplantation: is hepatitis C to blame? Liver Transpl., 2003, 9, 1019-1024.
23. Ghobrial, R. M.: Retransplantation for recurrent hepatitis C. Liver Transpl., 2002, 8 (10 B Suppl.), S38-S43.
24. Ghabril, M., Dickson, R., Wiesner, R.: Improving outcomes of liver retransplantation: an analysis of trends and the impact of HCV infection. Am. J. Transplant., 2008, 8, 404-411.
25. Burton, J. R. jr., Sonnenberg, A., Rosen, H. R., et al.: Retransplantation for recurrent hepatitis C in the MELD era: maximizing utility. Liver Transpl., 2004, 10 (10 Suppl), S59-S64.
26. Nellore, A., Fishman, J. A.: NK cells, innate immunity and hepatitis C infection after liver transplantation. Clin. Inf. Dis., 2011, 52, 369-377.
27. Nemes, B., Gelley, F., Zdori, G., et al.: New-onset diabetes mellitus and liver transplantation, with special consideration of recurrent hepatitis C. [De novo diabetes s mjtltets, klns tekintettel a hepatitis C-v-rus kijulsra.] Orv. Hetil., 2010, 151, 1062-1071. [Hungarian]
28. Subramanian, V., Seetharam, A. B., Vachharajani, N., et al.: Donor graft steatosis influences immunity to hepatitis C virus and allograft outcome after liver transplantation. Transplantation, 2011, 92, 1259-1268.
29. Wiesner, R. H., Demetris, A. J., Belle, S. H., et al.: Acute hepatic allograft rejection: incidence, risk factors and impact on outcome. Hepatology, 1998, 28, 638-645.
30. Ishii, N., Watashi, K., Hishiki, T., et al.: Diverse effects of cyclosporine on hepatitis C virus strain replication. J. Virol., 2006, 80, 4510-4520.
31. Hirano, K., Ichikawa, T., Nakao, K., et al.: Differential effects of calcineurin inhibitors, of tacrolimus and cyclosporin A on interferon-induced antiviral protein in human hepatocyte cells. Liver Transpl., 2008, 14, 292-298.
32. Levy, G., Grazi, G. L., Sanjuan, F., et al.: 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transpl., 2006, 12, 1464-1472.
33. Rubin, A., Aguilera, V., Berenguer, M.: Liver transplantation and hepatitis C. Clin. Res. Hepatol. Gastroenterol., 2011, 35, 805-812.
34. Gerlei, Zs., Srvry, E., Lengyel, G., et al.: Measurement and clinical significance of interleukin 28B in hepatitis C virus-infected liver transplant patients. Transplant. Proc., 2012, 44, 2154-2156.
35. Murakami, Y., Tanaka, M., Toyoda, H., et al.: Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C. BMC Med. Genomics, 2010, 3, 48.
36. Asselah, T., Biche, I., Sabbagh, A., et al.: Gene expression and hepatitis C virus infection. Gut, 2009, 58, 846-858.